- Home
- KLXE vs CUE Comparison
KLXE vs CUE Comparison
Compare KLXE & CUE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | KLXE | CUE |
|---|---|---|
| Founded | 2018 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Oilfield Services/Equipment | Biotechnology: Pharmaceutical Preparations |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 35.8M | 49.6M |
| IPO Year | N/A | 2018 |
Fundamental Metrics
Financial Performance| Metric | KLXE | CUE |
|---|---|---|
| Price | $1.97 | $0.33 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $3.00 |
| AVG Volume (30 Days) | 215.1K | ★ 1.5M |
| Earning Date | 11-05-2025 | 11-12-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $645,200,000.00 | $7,100,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $25.00 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $1.46 | $0.23 |
| 52 Week High | $7.40 | $1.75 |
Technical Indicators
Market Signals| Indicator | KLXE | CUE |
|---|---|---|
| Relative Strength Index (RSI) | 61.02 | 39.25 |
| Support Level | $1.49 | $0.23 |
| Resistance Level | $1.73 | $0.33 |
| Average True Range (ATR) | 0.13 | 0.05 |
| MACD | 0.02 | 0.00 |
| Stochastic Oscillator | 93.88 | 39.65 |
Price Performance
Historical ComparisonAbout KLXE KLX Energy Services Holdings Inc.
KLX Energy Services Holdings Inc is a provider of completion, intervention and production services and products to the onshore oil and gas producing regions of the United States. It serves the companies engaged in the exploration and development of onshore conventional and unconventional oil and natural gas reserves. Its products and services offerings include surface facilities and equipment, pressure control services, wireline services, fishing services, and engineered products. The company's segments include Southwest; Rocky Mountains and Northeast/Mid-Con region. It derives maximum revenue from Northeast/Mid-Con region.
About CUE Cue Biopharma Inc.
Cue Biopharma Inc is a clinical-stage biopharmaceutical company. It is developing a novel and proprietary class of biologics drugs for the selective modulation of the human immune system to treat a broad range of cancers and autoimmune disorders. Its objective is to provide patients suffering from cancer and autoimmune diseases with dramatically improved therapeutic outcomes through the platform of biologic drug product candidates. The other products under pipeline are CUE-101 as a Monotherapy, CUE-101 + Pembrolizumab, CUE-102, CUE-103, and others.